NASDAQ: VTGNVistagen Therapeutics Inc Stock
$2.99-0.02 (-0.66%)
Updated Jan 22, 2025
VTGN Price
$2.99
Fair Value Price
$6.03
Market Cap
$83.25M
52 Week Low
$2.22
52 Week High
$5.74
P/E
-2.41x
P/B
0.9x
P/S
105.29x
PEG
N/A
Dividend Yield
N/A
Revenue
$875.70k
Earnings
-$39.57M
Gross Margin
100%
Operating Margin
-4,517.15%
Profit Margin
-4,518.1%
Debt to Equity
0.1
Operating Cash Flow
-$33M
Beta
1.51
Next Earnings
Feb 11, 2025
Ex-Dividend
N/A
Next Dividend
N/A
VTGN Overview
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VTGN's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Value
D
Growth
D
Momentum
C
Sentiment
F
Safety
C
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VTGN
Ranked#451 of 555
Ranked#451 of 555
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $21.81 | A | |
| $120.84 | A | |
| $5.92 | A |
Be the first to know about important VTGN news, forecast changes, insider trades & much more!
VTGN News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VTGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VTGN ($2.99) is undervalued by 50.39% relative to our estimate of its Fair Value price of $6.03 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
VTGN ($2.99) is significantly undervalued by 50.39% relative to our estimate of its Fair Value price of $6.03 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
VTGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VTGN due diligence checks available for Premium users.
Valuation
VTGN fair value
Fair Value of VTGN stock based on Discounted Cash Flow (DCF)
Price
$2.99
Fair Value
$6.03
Undervalued by
50.39%
VTGN ($2.99) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VTGN ($2.99) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VTGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VTGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.41x
Industry
-191.09x
Market
30.67x
VTGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.9x
Industry
4.87x
VTGN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VTGN's financial health
Profit margin
Revenue
$183.0k
Net Income
-$13.0M
Profit Margin
-7,082.5%
VTGN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
VTGN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$102.5M
Liabilities
$9.5M
Debt to equity
0.1
VTGN's short-term assets ($99.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VTGN's short-term assets ($99.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VTGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VTGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.9M
Investing
-$7.8M
Financing
$0.0
VTGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VTGN vs Biotech Stocks
Vistagen Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.